RegenCell BioScience Holdings (RGC)

[shinhari1309]

&RGC Stock Price Movement

The Fed is hiking interest rates quickly in an attempt to calm rising inflation, which has affected many stock investors who are witnessing bleeding portfolios on their phones or PCs.

Companies are expected to cut profit forecasts in the coming quarter due to rising inflation rates and a potential decrease in earnings.

Investor Rick Rule told MoneyWise earlier this year, "I do not believe the broad equity market would take many rate rises."

The rule does not advocate selling all of one's holdings.

This takes us to a healthcare stock that had an IPO last year on July 22nd and had a terrific run of 300% capital gains after listing. Shares have taken a significant damage as a result of short sellers and hedge funds intentionally targeting the firm shares. RGC, on the other hand, has returned to the $30s, buoyed by positive research findings for Regencell's RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder contact, and market support for the shares.

The formulas proposed seek to treat the underlying causes of diseases while also easing symptoms and enhancing general health. RGC's TCM employs natural materials to treat diverse aspects in the body, and every physiological function is taken into account while formulating TCM formulations for patients.

Unlike other early-stage organisations, RGC has chosen a more open strategy that is well-aligned with shareholders' long-term interests.

Some highlights of the company's leaders and founders that demonstrate long-term commitment to the company:

- The CEO will get only a $1 yearly salary and no bonuses until the company's market valuation hits $1 billion.
- The CEO will continue to purchase back company shares to demonstrate his commitment to the firm and to strengthen its position against short and distort sellers.
- All directors and employees who were previously given stock options at the Company's IPO have agreed to a six-month lock-up following the vesting of their stock options. Because their stock options are slated to vest on July 16, 2022, their shares will be locked up until January 16, 2023.

RGC hopes to provide findings from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.

When the report is out, we will know if the firm has been making positive development on the company.

[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)